home.aspx
 
. https://biotechnology.report/Resources/Whitepapers/89f3a624-606a-44d2-9a38-8cbc20f83a8c_Is Your Biologic At Risk For Delays Disruptions Or Audits.pdf
whitepaper
SHARESHARESHARE
IS YOUR BIOLOGIC AT RISK FOR DELAYS, DISRUPTIONS OR AUDITS?
Thus, it’s no surprise that the world’s largest pharmaceutical companies have invested a combined $1.5 billion over the past five years to focus primarily on the advance of new biologics and biosimilars. While the North American economy represents a full 40 percent of this rapidly expanding market, the growth of overseas manufacturing facilities has created a network of opportunities for agile contract manufacturers around the world. DOWNLOAD